Jefferies Financial Group Boosts AstraZeneca (LON:AZN) Price Target to GBX 74

AstraZeneca (LON:AZN) had its price target boosted by Jefferies Financial Group from GBX 71 ($0.90) to GBX 74 ($0.94) in a research report released on Tuesday morning, MarketBeat Ratings reports. The brokerage currently has a hold rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also issued reports on AZN. Citigroup reissued a buy rating on shares of AstraZeneca in a research report on Tuesday, May 28th. Berenberg Bank upped their target price on shares of AstraZeneca from £130 ($164.43) to £150 ($189.73) and gave the company a buy rating in a research note on Friday, June 7th. Barclays restated an overweight rating and issued a £125 ($158.11) target price on shares of AstraZeneca in a research note on Monday, April 8th. JPMorgan Chase & Co. restated an overweight rating on shares of AstraZeneca in a research note on Tuesday, June 4th. Finally, Shore Capital restated a buy rating on shares of AstraZeneca in a research note on Tuesday, May 21st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, AstraZeneca currently has a consensus rating of Moderate Buy and a consensus price target of £105.53 ($133.49).

AstraZeneca Price Performance

AstraZeneca stock opened at £121.06 ($153.12) on Tuesday. AstraZeneca has a 52-week low of GBX 9,461 ($119.67) and a 52-week high of £127.04 ($160.69). The firm has a fifty day moving average of £122.82 and a 200-day moving average of £111.13. The firm has a market capitalization of £187.64 billion, a P/E ratio of 3,885.60, a PEG ratio of 0.97 and a beta of 0.16. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 92.51.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.